CD4 and relapsing-remitting multiple sclerosis: Our findings underscore the potential of AHSCT to profoundly reset the immune system in RRMS, selectively depleting pathogenic Th1/Th17 CD4 T cells and expanding regulatory or exhausted PD-1+ subsets in CD4 and CD8 T cells.